$2.61
00.00%
Pre-Market: Jul 19, 4:01 PM EDT
15 minutes delayed
Comments
Loading...
Nautilus Biotechnology
NAUTNASDAQ
Nautilus Biotechnology (NASDAQ:NAUT) Stock, Analyst Ratings, Price Targets, Forecasts
Nautilus Biotechnology Inc has a consensus price target of $4.25 based on the ratings of 5 analysts. The high is $6 issued by Guggenheim on June 27, 2024. The low is $2 issued by Goldman Sachs on August 3, 2022. The 3 most-recent analyst ratings were released by Guggenheim, Jefferies, and Morgan Stanley on June 27, 2024, June 3, 2024, and August 3, 2023, respectively. With an average price target of $5 between Guggenheim, Jefferies, and Morgan Stanley, there's an implied 91.57% upside for Nautilus Biotechnology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Jefferies
Morgan Stanley
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Nautilus Biotechnology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 129.89% | Guggenheim | Subbu Nambi | → $6 | Initiates | → Buy | Get Alert |
| 06/03/2024 | Buy Now | 14.94% | Jefferies | Tycho Peterson | $5 → $3 | Assumes | Buy → Hold | Get Alert |
| 08/03/2023 | Buy Now | 129.89% | Morgan Stanley | Tejas Savant | $6 → $6 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/03/2022 | Buy Now | 129.89% | Morgan Stanley | Tejas Savant | $8 → $6 | Maintains | Equal-Weight | Get Alert |
| 08/03/2022 | Buy Now | -23.37% | Goldman Sachs | Matthew Sykes | $4 → $2 | Maintains | Neutral | Get Alert |
| 07/14/2022 | Buy Now | 53.26% | Goldman Sachs | Matthew Sykes | $5 → $4 | Maintains | Neutral | Get Alert |
| 04/13/2022 | Buy Now | 91.57% | Goldman Sachs | Matthew Sykes | $9 → $5 | Maintains | Neutral | Get Alert |
| 01/06/2022 | Buy Now | 206.51% | Morgan Stanley | Tejas Savant | → $8 | Initiates | → Equal-Weight | Get Alert |
| 11/02/2021 | Buy Now | — | Cowen & Co. | Max Masucci | — | Initiates | → Outperform | Get Alert |
| 08/04/2021 | Buy Now | 283.14% | Goldman Sachs | Matthew Sykes | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Nautilus Biotechnology (NAUT) stock?
The latest price target for Nautilus Biotechnology (NASDAQ:NAUT) was reported by Guggenheim on June 27, 2024. The analyst firm set a price target for $6.00 expecting NAUT to rise to within 12 months (a possible 129.89% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nautilus Biotechnology (NAUT)?
The latest analyst rating for Nautilus Biotechnology (NASDAQ:NAUT) was provided by Guggenheim, and Nautilus Biotechnology initiated their buy rating.
When was the last upgrade for Nautilus Biotechnology (NAUT)?
There is no last upgrade for Nautilus Biotechnology
When was the last downgrade for Nautilus Biotechnology (NAUT)?
There is no last downgrade for Nautilus Biotechnology.
When is the next analyst rating going to be posted or updated for Nautilus Biotechnology (NAUT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Nautilus Biotechnology (NAUT) correct?
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a initiated with a price target of $0.00 to $6.00. The current price Nautilus Biotechnology (NAUT) is trading at is $2.61, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.